4FRONT-1 - 4D-150-C003 - Clinical Trial

¿Cuál es el Propósito de este estudio?

People in this study will be part of it for about 110 weeks, which is a little more than 2 years. During that time, they will need to visit the study clinic at least 30 times. At each visit, they will have tests and check-ups that are part of their regular care and also for the study.

¿Cuál es la Condición que se está estudiando?

Macular Neovascularization Secondary to Age-Related Macular Degeneration (wet AMD)

¿Quién puede participar en el Estudio?

People in this study must:

- Be 50 years old or older.

- Have never had treatment for their eye condition before.

- Have never had a problem called retinal detachment, which is when part of the eye pulls away from where it should be.

Grupo etario
Adultos

¿Qué Implica?

This study is trying to find out how well a new medicine called 4D-150 works compared to a medicine called Eylea in adults who have a kind of eye disease called wet age-related macular degeneration (wet AMD). The medicine is given as a shot directly into the eye. The study also wants to make sure the new medicine is safe and lasts a long time.

Detalles del Estudio

Título Completo
A Phase 3, Randomized, Double-Masked, Active-Controlled Trial of a Single Intravitreal Injection of 4D-150 in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration (4FRONT-1) - 4D-150-C003
Investigador Principal
Majda Hadziahmetovic, MD
Especialista en oftalmología
Número de Protocolo
IRB: PRO00117562
NCT: NCT06864988
Fase
Phase III
ClinicalTrials.gov
Estado de inscripción
Abierto para inscripción
Apoye las investigaciones de Duke Health o honre a un ser querido con un regalo de homenaje.